Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

ShedRx vs Kongo

ShedRx
Graded #3Partner

Higher grade

vs+4
Kongo
Graded #13Editorial

Lower grade

The verdict

ShedRx takes it — 88/100 to 84/100.

ShedRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The widest formulation spread on the board — oral/sublingual routes plus standard injection.

Partner links are labeled — we may earn a commission at no cost to you. It never changes the grade.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
86
86
Dose & formulationShedRx +15
95
80
Clinical oversightEven
84
84
Labs & monitoringShedRx +2
84
82
FulfillmentShedRx +1
88
87
Contract termsShedRx +4
89
85
ShedRx · left barKongo · right bar

The numbers

MetricShedRxKongo
WeighScore88/10084/100
GradeB+B
Scorecard rank#3#13
Semaglutide$199/mo$119/mo
Tirzepatide$299/mo$229/mo
CoverageNot disclosedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
RelationshipPartnerEditorial
ShedRx

Graded #3 · B+

Strengths

  • Oral/sublingual options
  • Competitive tirzepatide pricing
  • Strong dose flexibility

Where it loses points

  • States-served not disclosed
  • Compounded only
Kongo

Graded #13 · B

Strengths

  • $119 semaglutide
  • All 50 states, LegitScript-verified
  • Both molecules

Where it loses points

  • Tirzepatide jumps to $229/mo
  • Injection-only
  • Monitoring detail sparse

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard